title: Excellent outcomes of children with CML treated with imatinib mesylate compared to that in pre-imatinib era.
abstract: Allogeneic hematopoietic stem cell transplantation (HSCT) and tyrosine kinase inhibitor have revolutionized the treatment of patients with chronic myeloid leukemia (CML). In this study, the clinical impact of HSCT and imatinib mesylate (IM) was retrospectively analyzed in 28 children with CML treated in our institutes from 1984 to 2008. Twelve patients were given oral IM. At 36 months after initiation of IM therapy, the complete cytogenetic response rate was 90.9%, and the major molecular response rate was 36.4%. Sixteen children received allogeneic HSCT without administration of IM. The stage of disease at transplantation was: first chronic phase (n = 10), second chronic phase (n = 2), accelerated phase (n = 2), and blastic crisis (n = 2). The progression rate was significantly lower in patients treated with IM than in those treated without IM (0 vs. 28.6%, p = 0.006). In summary, the survival outcomes of pediatric patients with CML were dramatically improved by treatment with IM compared to HSCT.
authors.affiliation: Department of Pediatrics, Nagoya University Graduate School of Medicine, 65 Tsuruma-Cho, Showa-ku, Nagoya, Aichi, 466-8650, Japan.
authors.forename: Hideki
authors.initials: H
authors.lastname: Muramatsu
authors.affiliation: Department of Pediatrics, Nagoya University Graduate School of Medicine, 65 Tsuruma-Cho, Showa-ku, Nagoya, Aichi, 466-8650, Japan.
authors.forename: Yoshiyuki
authors.initials: Y
authors.lastname: Takahashi
authors.affiliation: Department of Pediatric Hematology/Oncology, Japanese Red Cross Nagoya First Hospital, Nagoya, Aichi, Japan.
authors.forename: Hirotoshi
authors.initials: H
authors.lastname: Sakaguchi
authors.affiliation: Department of Pediatrics, Nagoya University Graduate School of Medicine, 65 Tsuruma-Cho, Showa-ku, Nagoya, Aichi, 466-8650, Japan.
authors.forename: Akira
authors.initials: A
authors.lastname: Shimada
authors.affiliation: Department of Pediatrics, Nagoya University Graduate School of Medicine, 65 Tsuruma-Cho, Showa-ku, Nagoya, Aichi, 466-8650, Japan.
authors.forename: Nobuhiro
authors.initials: N
authors.lastname: Nishio
authors.affiliation: Department of Pediatrics, Nagoya University Graduate School of Medicine, 65 Tsuruma-Cho, Showa-ku, Nagoya, Aichi, 466-8650, Japan.
authors.forename: Asahito
authors.initials: A
authors.lastname: Hama
authors.affiliation: Department of Pediatrics, Nagoya University Graduate School of Medicine, 65 Tsuruma-Cho, Showa-ku, Nagoya, Aichi, 466-8650, Japan.
authors.forename: Sayoko
authors.initials: S
authors.lastname: Doisaki
authors.affiliation: Department of Pediatrics, Nagoya University Graduate School of Medicine, 65 Tsuruma-Cho, Showa-ku, Nagoya, Aichi, 466-8650, Japan.
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Yagasaki
authors.affiliation: Department of Pediatric Hematology/Oncology, Japanese Red Cross Nagoya First Hospital, Nagoya, Aichi, Japan.
authors.forename: Kimikazu
authors.initials: K
authors.lastname: Matsumoto
authors.affiliation: Department of Pediatric Hematology/Oncology, Japanese Red Cross Nagoya First Hospital, Nagoya, Aichi, Japan.
authors.forename: Koji
authors.initials: K
authors.lastname: Kato
authors.affiliation: Department of Pediatrics, Nagoya University Graduate School of Medicine, 65 Tsuruma-Cho, Showa-ku, Nagoya, Aichi, 466-8650, Japan. kojimas@med.nagoya-u.ac.jp.
authors.forename: Seiji
authors.initials: S
authors.lastname: Kojima
mesh_terms: D000293:Adolescent; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001549:Benzamides; D002648:Child; D002675:Child, Preschool; D015331:Cohort Studies; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000628:therapy; D008297:Male; D010879:Piperazines / Q000627:therapeutic use*; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*; D012189:Retrospective Studies; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D000068877:Imatinib Mesylate